BRPI0919199B8 - suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formação - Google Patents

suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formação

Info

Publication number
BRPI0919199B8
BRPI0919199B8 BRPI0919199A BRPI0919199A BRPI0919199B8 BR PI0919199 B8 BRPI0919199 B8 BR PI0919199B8 BR PI0919199 A BRPI0919199 A BR PI0919199A BR PI0919199 A BRPI0919199 A BR PI0919199A BR PI0919199 B8 BRPI0919199 B8 BR PI0919199B8
Authority
BR
Brazil
Prior art keywords
suspension
submicrometric
formation
preparing
submicron
Prior art date
Application number
BRPI0919199A
Other languages
English (en)
Inventor
Asgharian Bahram
J Castillo Ernesto
A Chowhan Masood
Original Assignee
Alcon Res Ltd
Alcon Res Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41353867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919199(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd, Alcon Res Llc, Novartis Ag filed Critical Alcon Res Ltd
Publication of BRPI0919199A2 publication Critical patent/BRPI0919199A2/pt
Publication of BRPI0919199B1 publication Critical patent/BRPI0919199B1/pt
Publication of BRPI0919199B8 publication Critical patent/BRPI0919199B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

suspensões farmacêuticas submicrométricas estabilizadas e métodos para preparar as mesmas. a presente invenção refere-se a uma suspensão farmacêutica submicrométrica e a um método para preparar a suspensão submicrométrica. a suspensão submicrométrica é útil para administração de agente terapêutico relativamente hidrofóbico e/ou de baixa solubilidade. a suspensão submicrométrica e o método para preparar a suspensão submicrométrica empregam tipicamente um material polimérico que ajuda na prevenção da agregação do agente terapêutico.
BRPI0919199A 2008-09-19 2009-09-16 suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formação BRPI0919199B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9828008P 2008-09-19 2008-09-19
US61/098,280 2008-09-19
PCT/US2009/057065 WO2010033528A1 (en) 2008-09-19 2009-09-16 Stabilized pharmaceutical sub-micron suspensions and methods of forming same

Publications (3)

Publication Number Publication Date
BRPI0919199A2 BRPI0919199A2 (pt) 2015-12-15
BRPI0919199B1 BRPI0919199B1 (pt) 2020-10-27
BRPI0919199B8 true BRPI0919199B8 (pt) 2021-05-25

Family

ID=41353867

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919199A BRPI0919199B8 (pt) 2008-09-19 2009-09-16 suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formação

Country Status (26)

Country Link
US (3) US20100076045A1 (pt)
EP (2) EP2425815B1 (pt)
JP (3) JP5739809B2 (pt)
KR (1) KR101682924B1 (pt)
CN (2) CN102176898A (pt)
AR (2) AR073597A1 (pt)
AU (1) AU2009293400B2 (pt)
BR (1) BRPI0919199B8 (pt)
CA (1) CA2736106C (pt)
CL (1) CL2009001856A1 (pt)
CY (1) CY1119740T1 (pt)
DK (1) DK2425815T3 (pt)
ES (2) ES2657455T3 (pt)
HR (1) HRP20180050T1 (pt)
HU (1) HUE037933T2 (pt)
LT (1) LT2425815T (pt)
MX (1) MX348204B (pt)
NO (1) NO2425815T3 (pt)
PL (2) PL2328551T3 (pt)
PT (2) PT2425815T (pt)
RU (1) RU2521258C2 (pt)
SI (1) SI2425815T1 (pt)
TW (1) TWI580441B (pt)
UY (1) UY32095A (pt)
WO (1) WO2010033528A1 (pt)
ZA (1) ZA201101398B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
WO2010103120A1 (en) * 2009-03-12 2010-09-16 Medichem, S.A. New crystals of a benzoylbenzeneacetamide derivative
WO2012051575A2 (en) 2010-10-15 2012-04-19 Iscience Interventional Corporation Device for ocular access
WO2012077038A1 (en) * 2010-12-06 2012-06-14 Degama Berrier Ltd. Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
CN111700878A (zh) * 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US10500282B2 (en) * 2012-12-19 2019-12-10 Kashiv Biosciences, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
WO2016036588A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Pharmaceutical suspensions containing etoricoxib
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3037174A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
CA3136814A1 (en) * 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
AU5084693A (en) * 1993-08-20 1995-03-21 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
AU5967101A (en) * 2000-05-10 2001-11-20 Rtp Pharma Inc Media milling
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
RU2219910C2 (ru) * 2002-01-08 2003-12-27 Институт органической и физической химии им. А.Е.Арбузова КНЦ РАН Ветеринарный имплантируемый препарат иммуностимулирующего действия (варианты)
US7138468B2 (en) * 2002-03-27 2006-11-21 University Of Southern Mississippi Preparation of transition metal nanoparticles and surfaces modified with (CO)polymers synthesized by RAFT
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
WO2004064808A1 (en) * 2003-01-15 2004-08-05 Dow Global Technologies Inc. Drug particles obtained by freezing onto a cold surface
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
CA2539023A1 (en) 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
CA2603189A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
BRPI0919199A2 (pt) 2015-12-15
CY1119740T1 (el) 2018-09-05
KR101682924B1 (ko) 2016-12-06
RU2521258C2 (ru) 2014-06-27
ZA201101398B (en) 2012-04-25
US20100076045A1 (en) 2010-03-25
BRPI0919199B1 (pt) 2020-10-27
CN104688682A (zh) 2015-06-10
JP2017043637A (ja) 2017-03-02
HK1152258A1 (zh) 2012-02-24
US20140294970A1 (en) 2014-10-02
ES2592503T3 (es) 2016-11-30
PT2425815T (pt) 2018-01-31
LT2425815T (lt) 2018-01-25
US20170216228A1 (en) 2017-08-03
TW201014612A (en) 2010-04-16
SI2425815T1 (en) 2018-02-28
CL2009001856A1 (es) 2010-12-31
MX348204B (es) 2017-05-30
EP2425815B1 (en) 2017-10-25
JP2012503003A (ja) 2012-02-02
PL2425815T3 (pl) 2018-03-30
RU2011115211A (ru) 2012-10-27
NO2425815T3 (pt) 2018-03-24
CA2736106C (en) 2016-08-16
AR124648A2 (es) 2023-04-19
UY32095A (es) 2010-01-29
EP2328551A1 (en) 2011-06-08
WO2010033528A1 (en) 2010-03-25
MX2011002494A (es) 2011-04-07
CN102176898A (zh) 2011-09-07
PL2328551T3 (pl) 2017-04-28
AU2009293400A1 (en) 2010-03-25
AU2009293400B2 (en) 2015-05-07
AR073597A1 (es) 2010-11-17
TWI580441B (zh) 2017-05-01
EP2425815A1 (en) 2012-03-07
CA2736106A1 (en) 2010-03-25
ES2657455T3 (es) 2018-03-05
JP2015052020A (ja) 2015-03-19
DK2425815T3 (da) 2018-01-29
JP5739809B2 (ja) 2015-06-24
HRP20180050T1 (hr) 2018-02-09
PT2328551T (pt) 2016-09-22
HUE037933T2 (hu) 2018-09-28
KR20110054055A (ko) 2011-05-24
EP2328551B1 (en) 2016-06-15

Similar Documents

Publication Publication Date Title
UY32095A (es) Suspensiones submicrón farmacéuticas estabilizadas y métodos para formarlas
BR112017025631A2 (pt) composições oftálmicas aquosas, método de induzir ou aumentar a formação de lágrima, método de formação de aglomerados de ciclosporina a e uso de ciclosporina a
BR112012005969A2 (pt) forma de dosagem sólida oral contendo nanopartículas e processo de formulação da mesma usando gelatina de peixe
BRPI0909630B8 (pt) composição em suspensão aquosa particularmente adequada para injeção dentro do olho
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
BR112015013278A2 (pt) composição condicionadora de tecidos
MX2011013726A (es) Nanodispersión de un medicamento y proceso para su preparación.
CO6280502A2 (es) Una composicion farmaceutica
BRPI0818118B8 (pt) composição farmacêutica na forma de uma suspensão aquosa estabilizada de carisbamato e seu processo de formação
MX384519B (es) Composicion farmceutica que comprende plasminogeno y usos de este.
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
MX2016005764A (es) Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.
HN2011000864A (es) Particulas inhalables que comprenden tiotropio
NZ607103A (en) A water-in-oil type emulsion for treating a disease of the eye
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
AR065640A1 (es) Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
MX385243B (es) Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
BR112017018569A2 (pt) formulação estável para administração parentérica de tapentadol
CL2009002173A1 (es) Composicion farmaceutica con una liberacion pulsatil de sildenafil que posee fraccion una liberacion inmediata que contiene 5 a 100 mg de sildenafil y una fraccion de liberacion controlada que contiene 25 a 150 mg de sildenafil; proceso para prepararla, util para tratar disfuncion erectil.
DOP2011000032A (es) Composicion farmaceutica solida
BR112015003305A2 (pt) parafuso cirúrgico de elução de fármaco
MX374165B (es) Aducto de ciclodextrina-panobinostat
BR112014002293A2 (pt) processo para a preparação de uma dispersão estável de nanopartículas, dispersão produzida e seu uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF